OneMedNet (US:ONMD)2026-03-30 21:57Real World Data and Evidence - OneMedNet has established a network of 2,130 healthcare sites, enabling extensive access to regulatory-grade data for clinical imaging [26]. - The company launched its iRWDTM solution in 2019, becoming the first Real World Data solution for life science companies, leveraging its existing technology and customer base [25]. - Approximately 90% of healthcare data, by size, is associated with imaging, highlighting the significant role of imaging in patient diagnosis [33]. - In 2020, there were 28 oncology product submissions that included Real World Data, indicating a growing reliance on such data for regulatory decision-making [54]. - OneMedNet's data is fully de-identified and ready for use, eliminating the need for data manipulation by life science users [41]. - The company employs AI/ML technology for data curation, ensuring high accuracy and compliance with regulatory standards [36]. - Real World Evidence derived from OneMedNet's data can support regulatory submissions, enhancing the approval process for new medical products [50]. - The integration of AI in Real World Data processing is expected to improve the quality and speed of insights for pharmaceutical and biotech companies [55]. - OneMedNet's focus on regulatory-grade imaging RWD curation positions it as a leader in the field, addressing the complex needs of life science organizations [36]. - The global Real World Evidence solutions market size was estimated at USD $2.6 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030 [86]. - The FDA launched the Real World Evidence Program in December 2022 to support regulatory decisions and develop consistent decision-making processes regarding Real World Evidence [87]. - The COVID-19 pandemic accelerated the adoption of Real World Evidence solutions, exemplified by the collaboration between ConcertAI and the FDA to generate Real World Evidence for cancer treatment [89]. - Real World Evidence is increasingly recognized by regulatory authorities, with the FDA expected to conduct its first full post-market safety approval using only Real World Evidence [71]. - Real World Evidence provides valuable insights into drug usage and safety, aiding life sciences companies in post-market surveillance and regulatory compliance [77]. - The FDA has emphasized the importance of Real World Evidence in monitoring post-market safety and adverse events, utilizing it to inform regulatory decisions [84]. - The demand for enhanced Real World Evidence capabilities is driving market growth, reflecting a shift from volume to value-based care in the life sciences industry [86]. - The global Real World Evidence solutions market is projected to grow from $2.62 billion in 2024 to $4.55 billion by 2030, at a CAGR of 8.2% [95]. - The global Real World Data market is estimated to be valued at $7.51 billion in 2024, with a forecasted CAGR of 9.1% from 2024 to 2031 [92]. - In 2021, the real world datasets segment accounted for 51.2% of the global Real World Evidence solutions market [92]. - Regulatory agencies like EMA and FDA are increasingly utilizing Real World Evidence in decision-making processes, driving demand for Real World Data solutions [95]. Financial Performance - The company generated net losses of $2.8 million and $10.1 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of approximately $104.4 million as of December 31, 2025 [131][134]. - Total revenue for the year ended December 31, 2025, was $1.4 million, an increase of 111% compared to $0.6 million in 2024, primarily driven by a $1.0 million increase in data delivery revenue [220]. - Data delivery revenue (iRWD) increased by 329% to $1.3 million in 2025, while subscription revenue (BEAM) decreased by 70% to $0.1 million due to the platform's decommissioning in May 2025 [220]. - Cost of revenue rose to $1.9 million in 2025, a 102% increase from $0.9 million in 2024, primarily due to higher data and curation charges associated with increased data delivery revenue [221]. - Gross margin for 2025 was negative $503,000, compared to negative $281,000 in 2024, reflecting the impact of rising costs relative to revenue [219]. - General and administrative expenses decreased by 9% to $6.4 million in 2025, down from $7.0 million in 2024 [219]. - Sales and marketing expenses increased by 53% to $1.3 million in 2025, compared to $0.8 million in 2024, indicating a strategic push in marketing efforts [219]. - Research and development expenses were $1.5 million in 2025, a slight increase of 3% from $1.5 million in 2024, reflecting ongoing investment in product development [219]. - Interest expense decreased by 54% to $67,000 in 2025, down from $147,000 in 2024, indicating improved debt management [219]. Corporate Developments - A subsidiary of Data Knights merged with OneMedNet Solutions Corporation on November 7, 2023, changing its name to OneMedNet Corporation [100]. - The business combination completed on November 7, 2023, involved a total consideration of approximately $200 million, resulting in the rebranding of Data Knights to OneMedNet Corporation [201]. - The company plans to expand its sales network globally, focusing on Imaging AI, medical device companies, and pharmaceutical companies [95]. - The company aims to enhance its service offerings and expand its product portfolio into high-growth Real World Data and Real World Evidence solutions [96][98]. Risks and Challenges - The company faces significant risks related to competition in the Real World Data and Real World Evidence market, which is evolving and highly competitive [139]. - The company may encounter difficulties in managing growth, which could negatively impact operations and resource allocation [135]. - The company must continue to commit resources to develop its Real World Data and Real World Evidence technology to establish a competitive position [142]. - The company is increasingly dependent on information technology systems, and any security breaches could adversely affect its business and reputation [144][146]. - The company is subject to extensive government regulation and oversight, which could lead to increased costs and penalties if compliance is not maintained [150]. - The company has experienced significant legal scrutiny regarding privacy and security regulations, with potential severe penalties for violations [151]. - The company’s operations could be adversely affected by natural disasters and other catastrophic events, impacting service delivery and data integrity [153]. - The company faces risks related to bitcoin holdings, including potential loss due to security breaches and regulatory changes that could classify bitcoin as a security [159]. - The trading price of the company's common stock may be subject to extreme volatility, influenced by various market factors and operational performance [160]. - The company may face securities litigation following periods of market price volatility, which could divert management resources and incur substantial costs [162]. - The company’s ability to maintain its listing on Nasdaq is critical, as failure to meet listing requirements could impair stock liquidity and financing options [164]. - Principal stockholders hold significant influence over corporate actions, which could delay or prevent acquisitions or significant transactions [166]. - The company has identified material weaknesses in its internal control over financial reporting, which could lead to inaccuracies in financial statements and affect investor confidence [180]. - The company is in the process of remediating identified material weaknesses but cannot estimate when these efforts will be completed, posing risks to future financial reporting [181]. - The company faces significant increased expenses and administrative burdens as a public company, which could adversely affect its financial condition and results of operations [178]. - The company may not be able to raise additional capital on attractive terms, which could materially affect its operations and prospects [182]. Cybersecurity Measures - The company has implemented a comprehensive cybersecurity framework to protect its systems and sensitive information from unauthorized access [187]. - The company's cybersecurity program is overseen by the Audit Committee, which receives regular updates on critical issues related to information security risks [187]. - The company employs various data security technologies and practices, including multi-factor authentication and identity management, to safeguard its information infrastructure [188]. - The company has established global incident response procedures and training programs to enhance its cybersecurity posture and mitigate risks [190].